Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

March 8, 2024

https://www.globenewswire.com/news-release/2024/03/07/2842155/12565/en/Alimera-Sciences-Reports-Fourth-Quarter-and-Full-Year-2023-Results.html

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022
2023 Net Revenues up 49% to $80.8 million vs. 2022
Increases 2024 Revenue Guidance

ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq:ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.